Last reviewed · How we verify
Bay Ntn 33893 (imidacloprid)
Bay Ntn 33893 (generic name: imidacloprid) is a drug. It is currently FDA-approved.
Bay Ntn 33893 is a small molecule that acts as a systemic insecticide. It works by blocking nicotinic acetylcholine receptors in the nervous system of insects, preventing the transmission of stimuli.
At a glance
| Generic name | imidacloprid |
|---|---|
| Target | Neuronal acetylcholine receptor subunit alpha-3, Acetylcholine receptor subunit beta-like 2, Acetylcholine-binding protein |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
- Behavioral changes (agitated, excessive grooming, hiding, pacing, spinning)
- Discomfort (scratching, rubbing, head-shaking)
- Lethargy (protracted sleeping, poorly responsive)
- Hypersalivation
- Polydipsia
- Coughing and gagging
- Depression/lethargy
- Application site reactions (alopecia, pruritus, lesions, erythema)
- Decreased appetite
- Vomiting
- Hyperactivity
- Ataxia
Serious adverse events
- Death
- Moxidectin toxicity
- Respiratory infection/disease
- Panleukopenia
- Anaphylaxis
Key clinical trials
- MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
- Whole-body Vibration Training on the Elderly With Combined Bilateral Knee Osteoarthritis (NA)
- Effects of VR Training on Balance and Fall Risk of Patients With COPD (NA)
- Eatwell Clinical Trial (R01) (NA)
- Experimental Trial of an Employment-Based Housing Program for Adults at Risk of Homelessness: Housing Integrated With Residential Employment (NA)
- Getting to Zero Among HHI MSM in the American South (NA)
- Affordable Made-in-India Microspheres for Liver Cancer Therapy (PHASE1)
- Spinal Cord Stimulation for Parkinson's Disease Rehabilitation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bay Ntn 33893 CI brief — competitive landscape report
- Bay Ntn 33893 updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Bay Ntn 33893
What is Bay Ntn 33893?
Bay Ntn 33893 (imidacloprid) is a pharmaceutical drug.
What is the generic name of Bay Ntn 33893?
imidacloprid is the generic (nonproprietary) name of Bay Ntn 33893.
What development phase is Bay Ntn 33893 in?
Bay Ntn 33893 is FDA-approved (marketed).
What are the side effects of Bay Ntn 33893?
Common side effects of Bay Ntn 33893 include Behavioral changes (agitated, excessive grooming, hiding, pacing, spinning), Discomfort (scratching, rubbing, head-shaking), Lethargy (protracted sleeping, poorly responsive), Hypersalivation, Polydipsia, Coughing and gagging. Serious adverse events: Death, Moxidectin toxicity, Respiratory infection/disease, Panleukopenia.
What does Bay Ntn 33893 target?
Bay Ntn 33893 targets Neuronal acetylcholine receptor subunit alpha-3, Acetylcholine receptor subunit beta-like 2, Acetylcholine-binding protein.
Related
- Target: All drugs targeting Neuronal acetylcholine receptor subunit alpha-3, Acetylcholine receptor subunit beta-like 2, Acetylcholine-binding protein
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing